CR20160173A - Nuevo tratamiento de combinación para la leucemia mieloide aguda (lma) - Google Patents
Nuevo tratamiento de combinación para la leucemia mieloide aguda (lma)Info
- Publication number
- CR20160173A CR20160173A CR20160173A CR20160173A CR20160173A CR 20160173 A CR20160173 A CR 20160173A CR 20160173 A CR20160173 A CR 20160173A CR 20160173 A CR20160173 A CR 20160173A CR 20160173 A CR20160173 A CR 20160173A
- Authority
- CR
- Costa Rica
- Prior art keywords
- lma
- myeloid leukemia
- acute myeloid
- combination treatment
- new combination
- Prior art date
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 title 1
- 238000011284 combination treatment Methods 0.000 title 1
- 208000032839 leukemia Diseases 0.000 title 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960000684 cytarabine Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente invención se refiere a un producto farmacéutico que comprende: a) como primer componente un inhibidor de la interacción MDM2-p53, y b) como segundo componente, citarabina, como preparación combinada para la utilización secuencial o simultánea en el tratamiento del cáncer, particularmente de la LMA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361912152P | 2013-12-05 | 2013-12-05 | |
PCT/EP2014/076063 WO2015082384A1 (en) | 2013-12-05 | 2014-12-01 | Novel combination treatment for acute myeloid leukemia (aml) |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20160173A true CR20160173A (es) | 2016-06-08 |
Family
ID=52014047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20160173A CR20160173A (es) | 2013-12-05 | 2016-04-14 | Nuevo tratamiento de combinación para la leucemia mieloide aguda (lma) |
Country Status (31)
Country | Link |
---|---|
US (5) | US20160303158A1 (es) |
EP (1) | EP3077004B1 (es) |
JP (3) | JP6297695B2 (es) |
KR (1) | KR101862955B1 (es) |
CN (1) | CN105792847B (es) |
AR (1) | AR098576A1 (es) |
AU (1) | AU2014359422B2 (es) |
BR (1) | BR112016009669B1 (es) |
CA (1) | CA2926307C (es) |
CL (1) | CL2016001345A1 (es) |
CR (1) | CR20160173A (es) |
DK (1) | DK3077004T3 (es) |
EA (1) | EA201690785A1 (es) |
ES (1) | ES2785203T3 (es) |
HK (1) | HK1222808A1 (es) |
HR (1) | HRP20200566T1 (es) |
HU (1) | HUE049434T2 (es) |
IL (1) | IL244888B (es) |
LT (1) | LT3077004T (es) |
MA (1) | MA39040A1 (es) |
MX (1) | MX370618B (es) |
PE (1) | PE20160591A1 (es) |
PH (1) | PH12016500933A1 (es) |
PL (1) | PL3077004T3 (es) |
PT (1) | PT3077004T (es) |
RS (1) | RS60142B1 (es) |
SG (1) | SG11201604504VA (es) |
SI (1) | SI3077004T1 (es) |
TW (2) | TWI678204B (es) |
WO (1) | WO2015082384A1 (es) |
ZA (1) | ZA201602829B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8592377B2 (en) | 2007-03-28 | 2013-11-26 | President And Fellows Of Harvard College | Stitched polypeptides |
WO2012021874A1 (en) | 2010-08-13 | 2012-02-16 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles with thioether linkers |
MX358886B (es) | 2011-10-18 | 2018-08-31 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos. |
WO2014071241A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
PE20160591A1 (es) * | 2013-12-05 | 2016-06-11 | Hoffmann La Roche | Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma) |
TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
CN112245565A (zh) | 2014-09-24 | 2021-01-22 | 艾瑞朗医疗公司 | 拟肽大环化合物及其用途 |
KR102570210B1 (ko) | 2014-09-24 | 2023-08-23 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방 거대고리 및 이의 제제 |
WO2016154058A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
CN108348571B (zh) * | 2015-09-03 | 2022-03-22 | 艾瑞朗医疗公司 | 拟肽大环化合物及其用途 |
EP3347372A4 (en) | 2015-09-10 | 2019-09-04 | Aileron Therapeutics, Inc. | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 |
CN115282149A (zh) * | 2016-06-06 | 2022-11-04 | 细胞基因公司 | 用抗癌剂治疗血液恶性肿瘤 |
JP6848047B2 (ja) * | 2016-08-08 | 2021-03-24 | フェイ シアオ, | スピロインドロンポリエチレングリコールカーボネート系化合物及びその組成物、調製方法及びその使用 |
SI3541387T1 (sl) | 2016-11-15 | 2021-08-31 | Novartis Ag | Odmerek in režim za zaviralce interakcije HDM2-P53 |
CA3052543A1 (en) * | 2017-03-31 | 2018-10-04 | Novartis Ag | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors |
WO2020023502A1 (en) | 2018-07-23 | 2020-01-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
JP7126556B2 (ja) | 2018-09-28 | 2022-08-26 | 富士フイルム株式会社 | シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤 |
US20220142979A1 (en) * | 2019-07-26 | 2022-05-12 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition of mdm2 inhibitor and use thereof for preventing and/or treating disease |
JP2024519335A (ja) * | 2021-05-13 | 2024-05-10 | ンカルタ・インコーポレイテッド | がん免疫療法のための投薬レジメン |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE381332T1 (de) * | 2002-05-02 | 2008-01-15 | Merck & Co Inc | Tyrosinkinase-hemmer |
DE102005012681A1 (de) * | 2005-03-18 | 2006-09-21 | Weber, Lutz, Dr. | Neue 1,5-Dihydro-pyrrol-2-one |
US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
CN101773408B (zh) * | 2010-01-15 | 2012-04-04 | 平荧 | 多功能排针结合电凝固技术提升下垂皮肤的装置 |
JP2013523820A (ja) * | 2010-04-09 | 2013-06-17 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン | 疾患を処置する際に使用するためのmdm2阻害剤のバイオマーカー |
JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
US20120010235A1 (en) * | 2010-07-12 | 2012-01-12 | Xin-Jie Chu | N-substituted pyrrolidines |
US8993614B2 (en) * | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
US9216170B2 (en) * | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
PE20160591A1 (es) * | 2013-12-05 | 2016-06-11 | Hoffmann La Roche | Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma) |
US9657351B2 (en) * | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
-
2014
- 2014-12-01 PE PE2016000615A patent/PE20160591A1/es not_active Application Discontinuation
- 2014-12-01 AU AU2014359422A patent/AU2014359422B2/en active Active
- 2014-12-01 EA EA201690785A patent/EA201690785A1/ru unknown
- 2014-12-01 MX MX2016007170A patent/MX370618B/es active IP Right Grant
- 2014-12-01 KR KR1020167014756A patent/KR101862955B1/ko active IP Right Grant
- 2014-12-01 DK DK14808911.3T patent/DK3077004T3/da active
- 2014-12-01 PL PL14808911T patent/PL3077004T3/pl unknown
- 2014-12-01 RS RS20200394A patent/RS60142B1/sr unknown
- 2014-12-01 US US15/101,258 patent/US20160303158A1/en not_active Abandoned
- 2014-12-01 JP JP2016536634A patent/JP6297695B2/ja active Active
- 2014-12-01 LT LTEP14808911.3T patent/LT3077004T/lt unknown
- 2014-12-01 CN CN201480066531.9A patent/CN105792847B/zh active Active
- 2014-12-01 WO PCT/EP2014/076063 patent/WO2015082384A1/en active Application Filing
- 2014-12-01 SI SI201431551T patent/SI3077004T1/sl unknown
- 2014-12-01 SG SG11201604504VA patent/SG11201604504VA/en unknown
- 2014-12-01 ES ES14808911T patent/ES2785203T3/es active Active
- 2014-12-01 AR ARP140104469A patent/AR098576A1/es unknown
- 2014-12-01 EP EP14808911.3A patent/EP3077004B1/en active Active
- 2014-12-01 CA CA2926307A patent/CA2926307C/en active Active
- 2014-12-01 BR BR112016009669-0A patent/BR112016009669B1/pt active IP Right Grant
- 2014-12-01 HU HUE14808911A patent/HUE049434T2/hu unknown
- 2014-12-01 PT PT148089113T patent/PT3077004T/pt unknown
- 2014-12-03 TW TW107105068A patent/TWI678204B/zh active
- 2014-12-03 TW TW103142020A patent/TWI627954B/zh active
- 2014-12-04 US US14/560,086 patent/US9956243B2/en active Active
-
2016
- 2016-04-04 IL IL244888A patent/IL244888B/en active IP Right Grant
- 2016-04-14 CR CR20160173A patent/CR20160173A/es unknown
- 2016-04-25 ZA ZA2016/02829A patent/ZA201602829B/en unknown
- 2016-05-17 MA MA39040A patent/MA39040A1/fr unknown
- 2016-05-19 PH PH12016500933A patent/PH12016500933A1/en unknown
- 2016-06-02 CL CL2016001345A patent/CL2016001345A1/es unknown
- 2016-09-22 HK HK16111115.9A patent/HK1222808A1/zh unknown
-
2018
- 2018-02-21 JP JP2018028482A patent/JP6918724B2/ja active Active
-
2020
- 2020-02-19 US US16/794,991 patent/US20200253999A1/en not_active Abandoned
- 2020-04-07 HR HRP20200566TT patent/HRP20200566T1/hr unknown
-
2021
- 2021-02-05 JP JP2021017415A patent/JP2021091690A/ja active Pending
- 2021-05-19 US US17/324,248 patent/US20220031726A1/en not_active Abandoned
-
2023
- 2023-04-03 US US18/130,016 patent/US20230381215A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20160173A (es) | Nuevo tratamiento de combinación para la leucemia mieloide aguda (lma) | |
CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
CL2016000807A1 (es) | Amino heteroarilo benzamidas como inhibidores de quinasa. | |
CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
UY34566A (es) | 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
CL2015000711A1 (es) | Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer. | |
CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
MX356368B (es) | Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
CL2015002194A1 (es) | Inhbidores de erk y sus usos | |
AR102712A1 (es) | Agonistas parciales del receptor de insulina | |
CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
UY36075A (es) | Derivados de tubulisina | |
CL2014002257A1 (es) | Compuestos derivados de 6-alquinilo piridinas, como mimeticos smac; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o prevencion del cancer. | |
CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
CL2015000897A1 (es) | Composición farmacéutica que contiene un portador de oxígeno basado en hemoglobina para el tratamiento de focalización de cáncer y prevención de recurrencia de cáncer. | |
CL2015003343A1 (es) | Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. | |
AR125920A2 (es) | Composiciones que comprenden vortioxetina y donepezil | |
CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
CL2016001210A1 (es) | Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis. | |
CO2017000552A2 (es) | Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70 | |
MX2015009818A (es) | Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple. | |
DOP2015000298A (es) | Compuestos nuevos para el tratamiento del cáncer | |
CL2014001959A1 (es) | Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer. |